Kellett Wealth Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Kellett Wealth Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,340	Closed	-$210K	–	69
2022 Q1	$210K	Hold	2,340	–	–	0.17%	60
2021 Q4	$262K	Buy	+2,340	New	+$282K	0.2%	54

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Kellett Wealth Advisors's XBI Position: Q2 2022 in Review

Kellett Wealth Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 2,340 shares — an estimated $210K sold.

Kellett Wealth Advisors first reported a position in XBI in Q4 2021 and held it in 2 quarters. The position peaked at $262K in Q4 2021. 706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

Kellett Wealth Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
Kellett Wealth Advisors sold 2,340 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $210K.
Kellett Wealth Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 2 quarters.
Kellett Wealth Advisors's State Street SPDR S&P Biotech ETF position peaked at $262K in Q4 2021.
706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on Kellett Wealth Advisors's 13F filing for Q2 2022, filed 8 Aug 2022.